Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Belli

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Expert Opinion on Pharmacotherapy|January 23, 2018
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancerBruno Achutti Duso, Dario Trapani, Giulia Viale, et al.
Trends in Cancer|September 13, 2023
Variant allele frequency: a decision-making tool in precision oncology?Luca Boscolo Bielo, Dario Trapani, Matteo Repetto, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2020
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agentsPaolo Tarantino, Antonio Marra, Sara Gandini, et al.
Cancers|January 23, 2024
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor TargetingEdoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, et al.
Anticancer Research|December 1, 2010
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancerStefano Cereda, Michele Reni, Alessia Rognone, et al.
The Oncologist|May 8, 2024
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysisLuca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, et al.
The Oncologist|March 23, 2024
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of OncologyLuca Boscolo Bielo, Carmen Belli, Edoardo Crimini, et al.
Expert Opinion on Pharmacotherapy|May 22, 2026
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title: oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancerJulian David Etessami, Carmine Valenza, Pier Paolo Maria Berton Giachetti, et al.
Cancer Treatment Reviews|May 21, 2024
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast CancerLuca Boscolo Bielo, Dario Trapani, Eleonora Nicolò, et al.
Vaccines|February 26, 2026
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future DirectionsJorge Iranzo, Edoardo Giordano, Renato Maria Marsicano, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Expert Opinion on Pharmacotherapy|January 23, 2018
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancerBruno Achutti Duso, Dario Trapani, Giulia Viale, et al.
Trends in Cancer|September 13, 2023
Variant allele frequency: a decision-making tool in precision oncology?Luca Boscolo Bielo, Dario Trapani, Matteo Repetto, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2020
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agentsPaolo Tarantino, Antonio Marra, Sara Gandini, et al.
Cancers|January 23, 2024
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor TargetingEdoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, et al.
Anticancer Research|December 1, 2010
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancerStefano Cereda, Michele Reni, Alessia Rognone, et al.
The Oncologist|May 8, 2024
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysisLuca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, et al.
The Oncologist|March 23, 2024
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of OncologyLuca Boscolo Bielo, Carmen Belli, Edoardo Crimini, et al.
Expert Opinion on Pharmacotherapy|May 22, 2026
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title: oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancerJulian David Etessami, Carmine Valenza, Pier Paolo Maria Berton Giachetti, et al.
Cancer Treatment Reviews|May 21, 2024
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast CancerLuca Boscolo Bielo, Dario Trapani, Eleonora Nicolò, et al.
Vaccines|February 26, 2026
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future DirectionsJorge Iranzo, Edoardo Giordano, Renato Maria Marsicano, et al.
Pageof 5